![]() INITIUM is evaluating UV1 in combination with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with advanced unresectable or metastatic malignant melanoma, and it completed enrollment with 156 patients in July 2022. The trial had previously reached its primary end point of safety and tolerability, and no unexpected safety signals related to UV1 were reported.ĭata for 4-year OS rates across both cohorts of UV1-103 are expected to be reported in the second quarter of 2024. ![]() In cohort 2, adjuvant GM-CSF was given at 75 µg per UV1 vaccination. Patients in cohort 1 received adjuvant GM-CSF at 37.5 µg per UV1 vaccination. Other key exclusion criteria included prior systemic treatment for unresectable or metastatic melanoma other than BRAF/MEK inhibitors prior therapy with an anti–CTLA-4, anti–PD-1, anti–PD-L1, or anti–PD-L2 agents or an oncolytic virus and a known hypersensitivity to granulocyte-macrophage colony–stimulating factor (GM-CSF). Patients with uveal or ocular malignant melanoma were excluded. Patients also needed to have adequate blood, liver, and kidney function. Notably, prior treatment with BRAF and MEK inhibitors was permitted. UV1-103 was an open-label, multicenter trial that enrolled patients with stage IIIB, IIIC or IV melanoma who were previously untreated and were eligible to receive pembrolizumab. The median progression-free survival (PFS) was 18.9 months. Previously reported data from cohort 1 (n = 20) and cohort 2 (n = 10) of UV1-103 showed UV1 plus pembrolizumab elicited an objective response rate (ORR) of 57% and a complete response rate of 33%. As we await data from the first three randomized UV1 Phase II trials in the near-term, we are increasingly optimistic about UV1’s potential to benefit cancer patients.” “The UV1-103 study treats the same patient population as our phase 2 INITIUM. The data further strengthen the previously reported results from the study, including good safety for UV1 and the high number of complete responses in patients with metastatic malignant melanoma where surgery is not an option,” Jens Bjørheim, chief medical officer at Ultimovacs, stated in a news release. “We are very encouraged to report a durable and long-term OS rate at the 4-year follow-up in the UV1-103 study. ![]() In both cohorts, the 1-, 2-, and 3-year OS rates were 86.7%, 73.3%, and 69.5%, respectively. The 1-, 2-, and 3-year OS rates for cohort 2 were 90%, 60%, and 60%, respectively. Using Kaplan-Meier estimates, the 1-, 2-, 3-, and 4-year OS rates for cohort 1 were 85.0%, 80.0%, 73.8%, and 73.8%, respectively. Notably, 1 patient included in the 3-year data could temporarily not be reached, and that patient’s 4-year OS outcome is pending. Previous data showed that the 3-year OS rate was 70.6% (n = 12/17), and updated findings showed that the 4-year OS rate was 68.8% (n = 11/16). First-line treatment with the universal cancer vaccine UV1 in combination with pembrolizumab (Keytruda) sustained overall survival (OS) in patients with advanced unresectable or metastatic malignant melanoma, according to updated data from cohort 1 of the phase 1 UV1-103 trial (NCT03538314).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |